Collaborative case study for academic center
Collaborative case study for academic center DANS (2021) has been hosted virtually in conjunction with…
About Us
OneCell DiagnosticsTM is an upcoming precision oncology company providing comprehensive genomic solutions for better cancer management. Our cutting-edge Next-Generation Sequencing technology in combination with strong bioinformatics platforms can help Oncologists devise precise and effective treatment/ testing options for patients at various stages of cancer, difficult or rare cancers or at risk for cancer.
Our tests are affordable, and offer deeper coverage of key actionable biomarkers that impact on initiation, development, progression and therapeutic evasion of the disease with high precision and reliability. These tests are well suited to detect ctDNA in liquid and tissue biopsies with high sensitivity and specificity.
Information for Patients
Cancer can be demanding and high cost of NGS-based comprehensive genomic profiling across the world which limits their use and precludes underprivileged patients from leveraging the strengths of these life-saving tests. We recognize this problem and are committed to transforming patient care by providing these tests at affordable rates and of international standards.
Information for Clinicians
We offer a diverse portfolio of affordable NGS based comprehensive genomic assays for multiple cancer types that can help identify key actionable biomarkers to help recommend rationale and validated precision treatment options for your patients including Chemotherapy, Targeted Therapy, and Immunotherapy.
Are you an Oncologist ?
Connect with us to work together for tests and clinical decision-making
Press Releases & Events
OneCellDx and Genetics Institute of America Partner to Launch OncoPredikt HRD Assay
- Ideal for HRD Screening Pharma Development
- AI Enabled Algorithm
- Poster Session at ASCO 2022
OneCellDx to Present Data on AI and ML-based HRD and CTC testing at 2022 American Society of Clinical Oncology, Annual Meeting
OneCellDx and Genetics Institute of America Partner to Launch OncoPredikt HRD Assay
- Ideal for HRD Screening Pharma Development
- AI Enabled Algorithm
- Poster Session at ASCO 2022
OneCellDx to Present Data on AI and ML-based HRD and CTC testing at 2022 American Society of Clinical Oncology, Annual Meeting
Press Releases & Events
Host‑dependent molecular factors
Host‑dependent molecular factors mediating SARS‑CoV‑2 infection Lorem Ipsum is simply dummy text of the printing…